Oehrlein, Elisabeth M.
Harris, Jason
Balch, Alan
Furlong, Pat
Hargis, Eric
Woolley, Mary
Perfetto, Eleanor
Funding for this research was provided by:
Amgen
Article History
First Online: 21 October 2020
Declarations
:
: Amgen provided funding for the Summit described in this manuscript. Amgen staff did not have any role in content development or manuscript preparation, and did not take part in meetings, survey preparation, data analysis, and/or interpretation. Content development was led by the Steering Committee with input from the Task Force. The National Health Council was engaged by Amgen to lead manuscript development with direction from the broader Steering Committee. EO, JH (formerly), and EP are employees of the National Health Council, which is a not-for-profit membership organization. It is supported through membership dues and sponsorship funds. The complete list of members and sponsors is located on the website at ExternalRef removed. JH worked at the National Health Council at the time of the development of this document. He is currently an employee of the Lupus Foundation of America and has no conflicts of interest to report. EP is also part-time faculty at the University of Maryland Baltimore School of Pharmacy. EP has received research funding from the Food and Drug Administration, Excerpta Medica, Pfizer, Merck and Co, PhRMA. AB is currently an employee of the Patient Advocate Foundation, and has no conflicts of interest to report related to the content or development of this Letter to the Editor. PF is the founding president of Parent Project Muscular Dystrophy and has no conflicts of interest to report. EH is an employee of the Colon Cancer Alliance and has no conflicts of interest to report. MW is an employee of Research!America and has no conflicts of interest to report.